Intermittent screening and treatment with artemether–lumefantrine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria

Table 3 Factors associated with third-trimester anaemia (< 11 g/dl) in study women (ATP analysis)

	Unadjusted Risk Ratio	(95% CI)^a	p-value^b	Adjusted Risk Ratio	(95% CI)	p-value
Treatment group
ISTp-AL	0.83	0.57–1.20	0.318	0.81	0.57–1.17	0.259
IPTp-SP	1			1
Age category
≤ 25	1			1
26–30	1.07	0.67–1.72	0.766	0.95	0.59–1.52	0.824
≥ 31	1.31	0.81–2.12	0.279	1.03	0.61–1.75	0.899
Baseline parasitaemia
Yes	1.49	0.90–2.45	0.119	1.46	0.89–2.41	0.138
No	1			1
Gravidity
Primigravidae	0.57	0.38–0.87	0.008	0.59	0.37–0.93	0.024
Secundigravidae	0.67	0.42–1.08	0.104	0.66	0.41–1.06	0.087
Multigravidae	1			1

CI confidence interval
^ap ≤ 0.05 means observed differences between comparison groups is statistically significant or not significant if p > 0.05
^bRisk ratios were modelled using binomial regression. Treatment group, age category, baseline parasitaemia and gravidity were included in the final model

ISSN: 1475-2875